Arrowhead Pharmaceuticals Stock Forecast for 2023 - 2025 - 2030
Updated on 04/23/2024
Arrowhead Pharmaceuticals Stock Forecast and Price Target
The average target price for Arrowhead Pharmaceuticals's stock set by renowned analysts in recent months is $55.00, representing a potential upside of approximately 129.93% from its last closing price if met by 2025. This estimation is based on a high estimate of $90.00 and a low estimate of $28.00. If you're interested in ARWR stock, it's important to compare it to other companies in the industry.
129.93% Upside
Arrowhead Pharmaceuticals Fair Value Forecast for 2023 - 2025 - 2030
In the last four years, Price for Arrowhead Pharmaceuticals has grown by 100.00%, going from $0.00 to $0.00. In the coming year, analysts are expecting an increase in Fair Value, predicting it will reach $25.09 – an increase of 100.00%. Over the next seven years, experts anticipate that Fair Value growth for Arrowhead Pharmaceuticals will be 100.00%.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| ABBV Stock Forecast | AbbVie | Outperform |
9
|
$167.89 | Buy/Sell | $178.42 | 12.57% |
| AMGN Stock Forecast | Amgen | Outperform |
4
|
$271.91 | Buy/Sell | $303.65 | 16.67% |
| GILD Stock Forecast | Gilead Sciences Inc | Outperform |
11
|
$66.95 | Buy/Sell | $87.82 | 19.49% |
| ALXN Stock Forecast | Alexion Pharmaceuticals | - |
0
|
$182.50 | Buy/Sell | $177.38 | -100.00% |
| BIIB Stock Forecast | Biogen | Outperform |
10
|
$194.11 | Buy/Sell | $299.62 | 50.43% |
Arrowhead Pharmaceuticals Revenue Forecast for 2023 - 2025 - 2030
In the last three years, Revenue for Arrowhead Pharmaceuticals has grown by 173.60%, going from $87.99M to $240.74M. In the following year, 15 experts forecast Arrowhead Pharmaceuticals's Revenue will decrease by 29.57%, to $169.55M. Over the next seven years, experts anticipate that Revenue growth for Arrowhead Pharmaceuticals will be 715.50%.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| BMRN Stock Forecast | BioMarin Pharmaceutical | Outperform |
10
|
$89.49 | Buy/Sell | $111.56 | 22.36% |
| INCY Stock Forecast | Incyte | Outperform |
9
|
$51.92 | Buy/Sell | $77.05 | 48.69% |
| ARNA Stock Forecast | Arena Pharmaceuticals | - |
6
|
$99.99 | Buy/Sell | $100.00 | -100.00% |
.jpg)
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| BPMC Stock Forecast | Blueprint Medicines | Outperform |
6
|
$90.61 | Buy/Sell | $85.71 | 10.36% |
| FOLD Stock Forecast | Amicus Therapeutics | Outperform |
7
|
$10.82 | Buy/Sell | $17.90 | 84.84% |
| CCXI Stock Forecast | ChemoCentryx | - |
8
|
$51.99 | Buy/Sell | $52.00 | -100.00% |
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| CBAY Stock Forecast | CymaBay Therapeutics | - |
8
|
$32.44 | Buy/Sell | $27.73 | -100.00% |
| VKTX Stock Forecast | Viking Therapeutics | Buy |
5
|
$63.85 | Buy/Sell | $34.00 | 80.11% |
| IOVA Stock Forecast | Iovance Biotherapeutics | Buy |
4
|
$11.32 | Buy/Sell | $20.42 | 125.27% |
Arrowhead Pharmaceuticals EBITDA Forecast for 2023 - 2025 - 2030
In the last three years, Arrowhead Pharmaceuticals's EBITDA has grown, increasing from $-87.22M to $-192.51M – an increase of 120.72%. For next year, the 4 analysts predict EBITDA of $-342.57M, which would mean an increase of 77.95%. Professionals believe that By 2030, Arrowhead Pharmaceuticals's EBITDA will fall to $571.50M – a 396.87% decrease from its current value.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| DRNA Stock Forecast | Dicerna Pharmaceuticals | - |
7
|
$38.01 | Buy/Sell | $35.06 | -100.00% |
| ACAD Stock Forecast | ACADIA Pharmaceuticals | Outperform |
6
|
$16.99 | Buy/Sell | $33.78 | 76.57% |
| CLDX Stock Forecast | Celldex Therapeutics | Buy |
11
|
$38.85 | Buy/Sell | $63.29 | 98.20% |
Arrowhead Pharmaceuticals EBIT Forecast for 2023 - 2025 - 2030
Arrowhead Pharmaceuticals's EBIT has increased by 120.05% In the last three years, going from $-93.16M to $-205.00M. In the next year, analysts expect EBIT to reach $-322.88M – an increase of 57.50%. In 2030, professionals predict that Arrowhead Pharmaceuticals's EBIT will decrease by 658.72%, to $1.15B.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| VCEL Stock Forecast | Vericel | Buy |
8
|
$45.38 | Buy/Sell | $42.58 | 21.20% |
| ARDX Stock Forecast | Ardelyx | Buy |
11
|
$6.51 | Buy/Sell | $9.94 | 115.05% |
| DVAX Stock Forecast | Dynavax Technologies | Outperform |
11
|
$11.84 | Buy/Sell | $25.00 | 106.93% |
Arrowhead Pharmaceuticals EPS Price Prediction Forecast for 2023 - 2025 - 2030
In the last four years, EPS for Arrowhead Pharmaceuticals has grown by 100.00%, going from $-0.84 to $0.00. In the coming year, analysts are expecting an increase in EPS, predicting it will reach $-2.77 – an increase of 100.00%. Over the next seven years, experts anticipate that EPS growth for Arrowhead Pharmaceuticals will be 100.00%.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| AGIO Stock Forecast | Agios Pharmaceuticals | Outperform |
9
|
$30.21 | Buy/Sell | $40.00 | 43.99% |
| ADMA Stock Forecast | ADMA Biologics | Buy |
9
|
$6.20 | Buy/Sell | $6.00 | 29.03% |
| BCRX Stock Forecast | BioCryst Pharmaceuticals | Outperform |
7
|
$4.41 | Buy/Sell | $14.09 | 138.10% |
Site Navigation
.jpg)